0 CHECKOUT

Hepatitis A - Pipeline Review, Q4 2010

  • ID: 1464246
  • December 2010
  • 31 pages
  • Global Markets Direct
1 of 3

Hepatitis A - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Hepatitis A Infection Pipeline Review, Q4 2010”, provides an overview of the Hepatitis A Infection therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis A Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis A Infection. “Hepatitis A Infection-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis A Infection.
- A review of the Hepatitis A Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products READ MORE >

Note: Product cover images may vary from those shown
2 of 3



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A Overview
Therapeutics Development
An Overview of Pipeline Products for Hepatitis A
Hepatitis A Therapeutics under Development by Companies
Hepatitis A Therapeutics under Investigation by Universities/Institutes
Companies Involved in Hepatitis A Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
Variation Biotechnologies, Inc.
Universities/Institutes Involved in Hepatitis A Therapeutics Development
Hepatitis A Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Havrix + Infanrix + ActHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Havrix + M-M-RII + Varivax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaqta + Infanrix + PedvaxHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaqta + PedvaxHIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Hepatitis A vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.